Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CSBR Champions Oncology

Pre-Market Trading 11-22 04:45:19 EST

4.27

-0.05

-1.16%

High4.67	Low4.27	Vol5.81K
Open4.39	D1 Closing4.32	Amplitude9.26%
Mkt Cap58.05M	Tradable Cap20.44M	Total Shares13.59M
T/O25.73K	T/O Rate0.12%	Tradable Shares4.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CSBR","market":"US","secType":"STK","nameCN":"Champions Oncology","latestPrice":4.27,"timestamp":1732222800000,"preClose":4.32,"halted":0,"volume":5806,"delay":0,"floatShares":4785992,"shares":13593766,"eps":-0.253947,"marketStatus":"Pre-Market Trading","change":-0.05,"latestTime":"11-22 04:45:19 EST","open":4.39,"high":4.67,"low":4.27,"amount":25729.1048,"amplitude":0.092593,"askPrice":5.69,"askSize":100,"bidPrice":1.72,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.253947,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.3,"volumeRatio":0.6615167372194319,"impliedVol":1.1755,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/CSBR/tweets","defaultTab":"tweets","newsList":[{"id":"2483027859","title":"New order for Alfa Laval to unlock potential of biofuels in aviation","url":"https://stock-news.laohu8.com/highlight/detail?id=2483027859","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483027859?lang=en_us&edition=fundamental","pubTime":"2024-11-13 16:35","pubTimestamp":1731486900,"startTime":"0","endTime":"0","summary":"LUND, Sweden, Nov. 13, 2024 /PRNewswire/ -- Driving the global energy transition towardsbiofuels, Alfa Laval has secured two contracts worth 350 millionSEK to supply cutting-edge HVO pre-treatment technology to Europe's largest biofuel facility. The facility, a joint venture between Cepsa Bioenergia San Roque S.L. , and Bio-Oils Energy, part of the Apical Group, will produce 500,000 tonnes of sustainable aviation fuel  and renewable diesel annually, addressing the growing demand for cleaner, renewable energy sources.Biofuels are crucial in the decarbonization of our societies, providing a low-carbon solution for existing technologies. In the transportation sector, they play a significant role in the shift towards net-zero emissions. However, the current demand for biofuels far exceeds the available supply, highlighting the need for increased production and innovation to meet this growing need.We pioneer technologies and solutions that free our customers to unlock the true potential of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tu2wkHZsb0a9TKrcRp08.g--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c6b7ac156550c59f71e72b0239e20fc8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tu2wkHZsb0a9TKrcRp08.g--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c6b7ac156550c59f71e72b0239e20fc8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/order-alfa-laval-unlock-potential-083500336.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/order-alfa-laval-unlock-potential-083500336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","ALFVF","CSBR","BK4161","ALFVY"],"gpt_icon":0},{"id":"2480057643","title":"Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2480057643","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480057643?lang=en_us&edition=fundamental","pubTime":"2024-11-04 18:52","pubTimestamp":1730717547,"startTime":"0","endTime":"0","summary":"Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Champions Oncology, Inc.  have had an unfortunate run in the last three years. Unfortunately, they have held through a 61% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 30% lower in that time. Unfortunately the share price momentum is still quite negative, with prices down 16% in thirty days.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Check out our latest analysis for Champions Oncology. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the rad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-nasdaq-csbr-shareholders-105227713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","NQmain","NDAQ","BK4585","BK4112","SQQQ","TQQQ",".IXIC","IE00B3QW5Z07.USD","IE00BKPKM429.USD","MNQmain","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","QLD","BK4588","BK4121","PSQ","QID","CSBR"],"gpt_icon":1},{"id":"2475133910","title":"Champions Oncology Signs Licensing Deal With Weill Cornell Medicine For Hematological Xenograft Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2475133910","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475133910?lang=en_us&edition=fundamental","pubTime":"2024-10-16 23:42","pubTimestamp":1729093356,"startTime":"0","endTime":"0","summary":"Champions Oncology  said Wednesday that it signed a licensing agreement with Weill Cornell Medicine, allowing it to distribute and commercialize the latter's hematological patient-derived xenograft models.Under the deal, Champions Oncology will have exclusive rights to offer services that use Weill Cornell Medicine's xenograft models for a limited time, according to the statement. The company said it will also serve as a repository for the models' distribution to academic institutions globally.No financial details were disclosed.Price: 4.45, Change: -0.09, Percent Change: -1.98","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2475914046","title":"Champions Oncology enters agreement with Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2475914046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475914046?lang=en_us&edition=fundamental","pubTime":"2024-10-16 23:10","pubTimestamp":1729091408,"startTime":"0","endTime":"0","summary":"Champions Oncology announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing, part of Enterprise Inno...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/champions-oncology-enters-agreement-with-weill-cornell-medicine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/champions-oncology-enters-agreement-with-weill-cornell-medicine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2476946934","title":"Champions Oncology Announces Agreement with Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2476946934","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476946934?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:55","pubTimestamp":1729090500,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. , a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing , part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft  models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center.The Center for Technology Licensing at Weill Cornell Medicine played a crucial role in negotiating the licensing agreement and brokering this relationship with Champions Oncology as part of Enterprise Innovation's mission to accelerate the best of biomedical innovation to market and tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-announces-agreement-weill-145500039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CSBR","PDX"],"gpt_icon":0},{"id":"2474367781","title":"Champions Oncology Inc (CSBR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2474367781","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474367781?lang=en_us&edition=fundamental","pubTime":"2024-10-10 07:00","pubTimestamp":1728514827,"startTime":"0","endTime":"0","summary":"Revenue: $14.1 million, an increase of 12% from the first quarter of 2024.Income from Operations: $1.3 million, compared to a loss of $2.6 million in the prior year.Adjusted EBITDA: $2 million, compared to an adjusted loss of $1.7 million in the year-ago period.Cost of Sales: $7 million, a decline of 6% from the previous year.Gross Margin: Improved to 50%, compared to 40% for the same period last year.R&D Expense: $1.5 million, a decline of $1.3 million from the year-ago period.Sales and Marketing Expense: $1.6 million, unchanged from the previous year.G&A Expense: $1.9 million, a decrease of $400,000 from the year-ago period.Cash Position: Ended the quarter with $2.9 million of cash and no debt.Cash Generated by Operating Activities: $300,000 for the quarter.GuruFocus has detected 4 Warning Signs with CSBR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Champions Oncology Inc  reported a strong revenue quarter, exceeding $14 million,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-inc-csbr-q1-230027590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR"],"gpt_icon":0},{"id":"2474058812","title":"Champions Oncology Inc (CSBR) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2474058812","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474058812?lang=en_us&edition=fundamental","pubTime":"2024-10-10 03:05","pubTimestamp":1728500748,"startTime":"0","endTime":"0","summary":"Annual Revenue: $15 million, a year-over-year decline of approximately $4 million or 7%.Annual Loss from Operations : $7.4 million compared to $5.3 million in 2023.Adjusted Annual Loss: $3.9 million compared to $1.3 million in the previous year.Fourth Quarter Revenue: $14 million, an increase of $900,000 or 7% from the previous year.Fourth Quarter Adjusted EBITDA: Approximately $900,000 compared to an adjusted loss of $900,000 in Q4 2023.Annual Cost of Sales: $29.1 million, a 1% increase from the previous year.Fourth Quarter Pharmacology Services Gross Margin: Expanded to 49% from 47% in the previous year.Annual Gross Margin: 43% for the full year.Fourth Quarter R&D Expense: Approximately $2 million, down from $2.8 million in the previous year.Annual R&D Expense: $9.5 million compared to $11.5 million in fiscal 2023.Fourth Quarter Sales and Marketing Expense: $1.8 million, relatively unchanged from the previous year.Annual Sales and Marketing Expense: $6.9 million compared to $6.8 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-inc-csbr-q4-190548123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR"],"gpt_icon":0},{"id":"2472643171","title":"Champions Oncology Reports Death of President Brady Davis","url":"https://stock-news.laohu8.com/highlight/detail?id=2472643171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472643171?lang=en_us&edition=fundamental","pubTime":"2024-10-04 00:11","pubTimestamp":1727971885,"startTime":"0","endTime":"0","summary":"Champions Oncology (CSBR) said Thursday that its president, Brady Davis, passed away unexpectedly this week.Davis had served as president since October 2023, the company said in a regulatory filing.Price: 4.65, Change: +0.14, Percent Change: +3.10","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRC","BK4087","BK4121","CSBR"],"gpt_icon":0},{"id":"2472100466","title":"Champions Oncology Announces Sudden Loss of President","url":"https://stock-news.laohu8.com/highlight/detail?id=2472100466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472100466?lang=en_us&edition=fundamental","pubTime":"2024-10-03 23:27","pubTimestamp":1727969261,"startTime":"0","endTime":"0","summary":"An update from Champions Oncology ( ($CSBR) ) is now available. Champions Oncology, Inc. has reported the unexpected passing of its President, Mr. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/champions-oncology-announces-sudden-loss-of-president?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/champions-oncology-announces-sudden-loss-of-president?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CSBR"],"gpt_icon":0},{"id":"2470441687","title":"Champions Oncology (NASDAQ:CSBR) Is In A Strong Position To Grow Its Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2470441687","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470441687?lang=en_us&edition=fundamental","pubTime":"2024-09-25 03:48","pubTimestamp":1727207328,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So should Champions Oncology  shareholders be worried about its cash burn?In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.When Might Champions Oncology Run Out Of Money?As you can probably tell by now, we're not too worried about Champions Oncology's cash","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-nasdaq-csbr-strong-194848718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","MNQmain","QID","LU2210149790.SGD","TQQQ","NDAQ","IE00BGHQF748.EUR","BK4112","CSBR","IE00B3QW5Z07.USD","BK4121","PSQ","IE00B64PRP62.GBP","NQmain","QLD","SQQQ","BK4585","LU2095319765.USD","BK4588",".IXIC","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2467388547","title":"Champions Oncology upgraded to buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2467388547","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467388547?lang=en_us&edition=fundamental","pubTime":"2024-09-13 02:59","pubTimestamp":1726167554,"startTime":"0","endTime":"0","summary":"Craig-Hallum upgraded Champions Oncology  to buy, commenting that it sees the contract research organization returning to revenue predictability over the next couple of quarters. “While management acknowledged that the near term may be a bit lumpy, positive trends with revenue conversion, lower cancellations and operational improvements are yielding better margins and are expected to be durable,” the investment firm said in its note.  Craig-Hallum said that the Biosecure Act could “also become a tailwind opening doors to new customers and contracts.”  The firm maintained its price target of $6 for the stock.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4149230-champions-oncology-upgraded-to-buy-by-craig-hallum","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CSBR"],"gpt_icon":0},{"id":"2466315275","title":"Champions Oncology Raised to Buy From Hold by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2466315275","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466315275?lang=en_us&edition=fundamental","pubTime":"2024-09-12 19:29","pubTimestamp":1726140540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CSBR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2024 07:29 ET (11:29 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2466333273","title":"Champions Oncology, Inc.  : Craig-Hallum  Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2466333273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466333273?lang=en_us&edition=fundamental","pubTime":"2024-09-12 19:11","pubTimestamp":1726139487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nAZN279XSI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2466260140","title":"Stocks to Watch: Oxford Industries, Mobile Infrastructure, Champions Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2466260140","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466260140?lang=en_us&edition=fundamental","pubTime":"2024-09-12 07:55","pubTimestamp":1726098900,"startTime":"0","endTime":"0","summary":"Oxford Industries cut its full-year outlook after posting lower-than-expected revenue and profit in the second quarter, as inflation-weary shoppers reined in discretionary spending. The owner of Tommy Bahama and Lilly Pulitzer posted per-share earnings $2.57 a share. Revenue edged 0.1% lower and missed Wall Street analysts' expectations. For the year, the company cut its revenue outlook to between $1.51 billion and $1.54 billion. Shares fall 10%, to $75.12, in after-hours trading.Mobile Infrastructure's board authorized a share-buyback program and the company entered into a new credit agreement. The agreement for a $40.4 million revolving credit facility will provide flexibility to fund future preferred stock redemptions in cash rather than common stock and allow it to commence the stock-repurchase plan. The company has agreed to issue 250,000 shares of common stock to the lender in connection with the revolving facility, and an additional 250,000 shares if the company draws $15 millio","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BEEP","BK4121","OXM","CSBR","BK4202"],"gpt_icon":0},{"id":"2466265327","title":"Champions Oncology Shares Jump After Swinging to Profit, Posting Higher Revenue in 1Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2466265327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466265327?lang=en_us&edition=fundamental","pubTime":"2024-09-12 05:30","pubTimestamp":1726090200,"startTime":"0","endTime":"0","summary":"Shares of Champions Oncology surged after the company swung to a profit and posted higher revenue in its fiscal first quarter.The stock rose 30% to $5.30 in after-hours trading Wednesday. Shares ended the regular session up 3% to $4.07, putting them down 28% since the beginning of the year.The Hackensack, N.J., biotechnology company, which provides end-to-end oncology solutions, posted net income of $1.3 million, or 9 cents a share, for its three months ended July 31, compared with a loss of $2.6 million, or 19 cents a share, in last year's quarter.Revenue rose 12% to $14.1 million, boosted by operational improvements and efficiencies that led to an increase in bookings-to-revenue conversion percentage.Chief Executive Ronnie Morris said, \"we're cautiously optimistic that we've weathered the worst of the business downturn, and we're poised to emerge leaner and stronger.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2466507192","title":"Champions Oncology Non-GAAP EPS of $0.11 beats by $0.14, revenue of $14.06M beats by $0.83M","url":"https://stock-news.laohu8.com/highlight/detail?id=2466507192","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466507192?lang=en_us&edition=fundamental","pubTime":"2024-09-12 04:36","pubTimestamp":1726086976,"startTime":"0","endTime":"0","summary":"Champions Oncology press release  (NASDAQ:CSBR): Q1  Non-GAAP EPS of $0.11  beats by $0.14.\nRevenue of $14.06M (+11.9% Y/Y)  beats by $0.83M.\nThe Company ended the quarter with cash on hand of approximately $2.9 million. The Company has no debt.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4148812-champions-oncology-non-gaap-eps-of-0_11-beats-0_14-revenue-of-14_06m-beats-0_83m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CSBR"],"gpt_icon":0},{"id":"2466252658","title":"Champions Oncology Q1 Adj $0.11 Beats $(0.03) Estimate, Sales $14.06M Beat $13.23M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2466252658","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466252658?lang=en_us&edition=fundamental","pubTime":"2024-09-12 04:04","pubTimestamp":1726085069,"startTime":"0","endTime":"0","summary":"Champions Oncology (NASDAQ:CSBR) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.03) by 466.67 percent. This is a 168.75 percent increase over losses of $(0.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40821639/champions-oncology-q1-adj-0-11-beats-0-03-estimate-sales-14-06m-beat-13-23m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Champions Oncology Q1 Adj $0.11 Beats $(0.03) Estimate, Sales $14.06M Beat $13.23M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2466252560","title":"Champions Oncology Q1 EPS USD 0.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2466252560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466252560?lang=en_us&edition=fundamental","pubTime":"2024-09-12 04:02","pubTimestamp":1726084923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240911:nPLXE02973:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2466571712","title":"Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2466571712","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466571712?lang=en_us&edition=fundamental","pubTime":"2024-09-12 04:00","pubTimestamp":1726084800,"startTime":"0","endTime":"0","summary":"HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.David Miller, CFO of Champions, added, \"The first quarter saw a return to profitability as revenue increased 12% to $14.1 million while we reduced total costs by more than $2.0 million. The revenue increase, combined with mostly unchanged cost of oncology services, lifted our margin to 50%.\" Miller added, \"While there will be some revenue and margin volatility over the coming quarters, our cost reductions should enable us to remain profitable on an adjusted EBITDA basis.\". Cost of oncology services was $7.1 million for the three-months ended July 31, 2024, a decrease of $612,000, or 8.0% compared to $7.7 million for the three-months ended July 31, 2023. The decrease in cost of oncology services was primarily fro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H7HeDNWVDxnQN9797eajOQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/baa49c0054705ac08f97cb63e8f8d24c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H7HeDNWVDxnQN9797eajOQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/baa49c0054705ac08f97cb63e8f8d24c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-200000263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR"],"gpt_icon":0},{"id":"2466645837","title":"Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Accolade (ACCD) and Champions Oncology (CSBR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466645837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466645837?lang=en_us&edition=fundamental","pubTime":"2024-09-10 20:50","pubTimestamp":1725972634,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Accolade (AC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harrow-health-hrow-accolade-accd-and-champions-oncology-csbr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harrow-health-hrow-accolade-accd-and-champions-oncology-csbr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACCD","HCSG","BK4137","BK4196","BK4007","BK4557","CSBR","HROW","BK4121"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.championsoncology.com","stockEarnings":[{"period":"1week","weight":-0.0426},{"period":"1month","weight":-0.0229},{"period":"3month","weight":-0.0787},{"period":"6month","weight":-0.0553},{"period":"1year","weight":-0.2236},{"period":"ytd","weight":-0.2402}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":0.073159},{"month":2,"riseRate":0.647059,"avgChangeRate":0.020937},{"month":3,"riseRate":0.388889,"avgChangeRate":0.027512},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.012535},{"month":5,"riseRate":0.5,"avgChangeRate":0.06583},{"month":6,"riseRate":0.444444,"avgChangeRate":0.037812},{"month":7,"riseRate":0.388889,"avgChangeRate":-0.027864},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.014946},{"month":9,"riseRate":0.611111,"avgChangeRate":0.101705},{"month":10,"riseRate":0.277778,"avgChangeRate":0.013574},{"month":11,"riseRate":0.388889,"avgChangeRate":-0.004999},{"month":12,"riseRate":0.529412,"avgChangeRate":0.087306}],"exchange":"NASDAQ","name":"Champions Oncology","nameEN":"Champions Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Champions Oncology(CSBR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Champions Oncology,CSBR,Champions Oncology股票,Champions Oncology股票老虎,Champions Oncology股票老虎国际,Champions Oncology行情,Champions Oncology股票行情,Champions Oncology股价,Champions Oncology股市,Champions Oncology股票价格,Champions Oncology股票交易,Champions Oncology股票购买,Champions Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Champions Oncology(CSBR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction